• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Babylon Delivers Exceptional H1 2021 Operational and Financial Results and Reaffirms Growth Guidance

    9/15/21 8:00:00 AM ET
    $KURI
    Get the next $KURI alert in real time by email

    PALO ALTO, Calif. and LONDON, Sept. 15, 2021 /PRNewswire/ -- Babylon Holdings Limited ("Babylon"), a world leading company reengineering how people engage with their health at every step of the care continuum, today announced its financial and operating results for the six months ended June 30, 2021.

    Ali Parsa, CEO and Founder of Babylon said: "Babylon again passed many milestones in the first half of 2021, growing revenue by 472% year on year. We continued to execute, putting us amongst the fastest growing companies worldwide, including in the US, where since our initial launch last year, we gained millions of covered members and, as of today, over 100,000 value-based lives."

    "But I believe we have not even really begun. We are on the verge of a fundamental overhaul in the global system of delivery of healthcare, with finally everything that is solid melting into air as it did years ago with other sectors like retail, finance and information. Out of this the healthcare sector will also emerge some of the world's most valuable and impactful companies by creating a more scalable, accessible and affordable value proposition worldwide."

    "We have the determination and the confidence to focus on this long-term goal, and not be distracted by short term glory. Babylon has one of the largest and most diverse collections of scientists, engineers and clinicians working together across the world, led by an accomplished management team with a proven track record, addressing affordability and accessibility of healthcare. We will continue to invest to create a powerful and unique combination of our digital-first, AI-enabled, comprehensive clinical services that will in time transform every touch point of the care continuum. I couldn't be more proud of our Babylonian team and we look at these results that were delivered by every Babylonian as just a confirmation that we are on the right path," said Parsa.

    Financial Results and Operating Metrics Summary

    Improvement in the following financial and operational metrics for the six months ended June 30, 2021, compared to the six months ended June 30, 2020:

    • Revenue totaled $128.8 million compared to $22.5 million, an increase of 472% year over year
    • Net loss improved to $75.7 million compared to a net loss of $90.8 million
    • Adjusted EBITDA loss improved to $54.2 million compared to a loss of $76.2 million
    • VBC member count in the U.S. was zero on June 30, 2020 versus ~84,000 on June 30, 2021
    • Coverage of residents under UK Babylon GP at Hand grew to over 102,000 on June 30, 2021, now largest GP practice in UK
    • In Rwanda, appointment volumes tripled from ~44,000 in June 2020 to ~132,000 in June 2021
    • Users2 increased 55% year-over-year to 8.2 million on June 30, 2021

    H1 2021 and Recent Highlights

    • On June 3, 2021, Babylon entered into a definitive merger agreement with Alkuri Global Acquisition Corp. (NASDAQ:KURI), a special purpose acquisition company; this combination is further supported by a $230 million PIPE – funded over 85% from new, institutional investors
    • In January 2021, TELUS acquired Babylon's Canadian venture and concurrently signed a long-term licensing deal to continue offering Babylon's innovative AI-driven digital health tools to TELUS' customers. This is Babylon's first long-term license of its digital platform including its telehealth capabilities and AI-tools together.
    • In June 2021, Babylon entered into an agreement to make its Babylon 360 solution available to ~15,000 members across New York state commencing on July 1, 2021, and combined with more members in Missouri and California, total VBC Members in the U.S. grew to over 100,000
    • Publication of peer-reviewed research in July 2021 affirmed that Babylon's digital-first model in the UK delivered 15% - 35% lower hospital care costs than the regional average3 – confirming Babylon's proprietary model of care can produce meaningful cost savings
    • In August 2021, Babylon announced that it was extending its partnership with the Royal Wolverhampton NHS Trust to introduce an integrated and accessible digital-first healthcare experience to be made available to ~55,000 Wolverhampton residents in October 2021
    • Babylon completed preparation for participation commencing January 2022 in one of the innovative VBC programs sponsored by CMS4 and CMMI5 and is awaiting finalization of CMS processes and approvals
    • Babylon accelerated its rate of product revisions and releases 4-fold, putting it in a category with other world-class technology companies

    1 Including GP at Hand members

    2 Number of members who have joined our digital platform and complete all mandatory fields on the digital platform

    3 Commissioned by Babylon Holdings and published in Journal of Medical Internet Research. Study compared spending per patient for Babylon GP at Hand to the regional average spending over a two-year period from April 1, 2018 to March 31, 2019 in North West London

    4 Centers for Medicare & Medicaid Services

    5 Center for Medicare & Medicaid Innovation

    Leadership Development

    Babylon has made substantial investment in its leadership team over the past year. These additions include:

    • Paul-Henri Ferrand, former President at Google Cloud and Dell, North America as the company's Chief Business Officer (CBO);
    • Steven Davis, former SVP and GM of AI and data at Expedia as the Chief Technology Officer (CTO);
    • Stacy Saal, former GM/COO of Prime Air at Amazon as the Chief Operating Officer (COO);
    • Yon Nuta, former Chief Product Officer at Gaia, Inc as the Chief Product Officer (CPO);
    • Samira Lowman, former VP, Organization and Talent Acquisition & Development at General Electric as Chief People Officer (CPO); and
    • Darshak Sanghavi, former Chief Medical Officer at United Healthcare and Optum as Global Chief Medical Officer (CMO).

    Balance Sheet

    As of June 30, 2021, the Company had cash and cash equivalents of $42.4 million.

    In August 2021, Babylon completed a debt offering of $50 million which is due to be repaid at the completion of the transaction with Alkuri Global Acquisition Corp.

    Financial Outlook

    "We're pleased with our first half results and strong execution of our growth plan, and we remain on track to deliver our 2021 revenue and adjusted EBITDA expectations," said Charlie Steel, Chief Financial Officer of Babylon. "Our business and operational momentum continue to accelerate as we enter the second half, and our world class team has us well positioned to further our track record of robust growth to achieve our revenue growth and objectives for 2022 and beyond."

    FY 2021 Financial Guidance

    For the twelve months ended December 31, 2021, the Company reiterates its previously provided outlook and continues to expect:

    • Revenue of ~$321 million
    • Adjusted EBITDA of ~ ($140) million

    These statements are forward-looking and actual results may differ materially. Please refer to the Forward-Looking Statements disclaimer below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

    Upon the closing of the definitive merger agreement with Alkuri Global Acquisition Corp., which is expected in October 2021, subject to receipt of Alkuri stockholder approval and the satisfaction of other customary closing conditions, the new company will become Babylon Holdings Limited and will be listed on the New York Stock Exchange under the ticker symbol BBLN. The transaction reflects an initial pro forma equity value of approximately $4.2 billion and is expected to deliver up to $575 million of gross proceeds to fund Babylon's pro forma balance sheet, including the contribution of up to $345 million of cash held in Alkuri Global's trust account assuming no redemptions. The combination is further supported by a $230 million PIPE - funded over 85% from new, institutional investors.

    A reconciliation of International Financial Reporting Standards ("IFRS") and non-IFRS results has been provided in the accompanying tables. An explanation of these measures is included in the supplemental tables to this press release.

    Accompanying supplemental information will be posted to the Investor Relations section of Babylon's web site at https://www.babylonhealth.com/us/investor-relations.

    About Babylon 

    Babylon is a world leading, digital-first, value-based care company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth.

    Babylon is re-engineering healthcare, shifting the focus from sick care to preventative healthcare so that patients experience better health, and reduced costs. This is achieved by leveraging a highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare. We endeavor to support patients' health needs, all from their devices, with the aim to promote longer and healthier lives. When sick, Babylon provides assistance to navigate the health system, connecting patients digitally to the right clinician 24/7, at no additional cost.

    Founded in 2013, we have since delivered millions of clinical consultations and AI interactions, with c.2m clinical consultations and c.3.9m AI interactions in 2020 alone. We work with governments, health providers and insurers across the globe, and support healthcare facilities from small local practices to large hospitals. For more information, please visit www.babylonhealth.com/us.

     

    Table 1

    Babylon Holdings Limited

    Consolidated Statement of Profit and Loss and Other Comprehensive Loss

    (In thousands, except per share amounts, unaudited)







     For the Six Months Ended June 30, 



    2021



    2020

     Revenue 

    $ 128,771



    $ 22,503

     Cost of care delivery  

    (92,137)



    (18,820)

     Platform & application expenses 



    (21,377)



    (12,898)

     Research & development expenses 

    (17,201)



    (20,881)

     Sales, general & administrative expenses 

    (76,606)



    (52,762)

     Operating loss 

    (78,550)



    (82,858)

     Finance costs 

    (2,243)



    (2,569)

     Finance income 

    28



    6

     Exchange (loss)  

    (91)



    (2,146)

     Net finance (expense) 

    (2,306)



    (4,709)









     Gain on sale of subsidiary 

    3,917



    -

     Share of loss of equity-accounted investees 

    (1,276)



    (309)

     Loss before taxation 

    (78,215)



    (87,876)

     Tax benefit / (provision)  

    2,493



    (2,937)

     Loss for the period 

    (75,722)



    (90,813)









     Other comprehensive loss 







     Items that may be reclassified subsequently to profit or loss:  







     Currency translation differences 

    (67)



    1,530

     Other comprehensive (loss) / gain for the period, net of income tax 

    (67)



    1,530

     Total comprehensive loss for the period  

    (75,789)



    (89,283)









     Loss attributable to:  







     Equity holders of the parent 

    (74,907)



    (89,984)

     Non-controlling interest 

    (815)



    (829)



    (75,722)



    (90,813)

     Total comprehensive loss attributable to: 







     Equity holders of the parent 

    (74,974)



    (88,454)

     Non-controlling interest 

    (815)



    (829)





    $ (75,789)



    $ (89,283)











     Net loss per share, Basic and Diluted 

    $ (0.09)



    $ (0.11)



     

     

    Table 2

    Babylon Holdings Limited

    Consolidated Statement of Cash Flows

    (In thousands, unaudited)













     For the Six Months Ended June 30, 



    2021



    2020

     Cash flows from operating activities 







     Loss for the period 

    $ (75,722)



    $ (90,813)

     Adjustments for: 







     Finance costs 

    2,243



    2,569

     Finance income 

    (28)



    (6)

     Depreciation and amortization 

    13,322



    6,459

     Share-based compensation 

    12,344



    433

     Taxation 

    (2,493)



    2,937

     Exchange loss  

    91



    2,146

     Gain on disposal of subsidiary 

    (3,917)



    -

     Impairment expense 

    -



    32

     Share of net loss of associates and joint ventures 

    1,276



    309



    (52,884)



    (75,934)

     Working capital adjustments: 







     (Increase) in trade and other receivables 

    (12,414)



    (8,291)

     Increase/(Decrease) in trade and other payables 

    43,604



    (3,166)

     Decrease in assets/liabilities held for sale 

    1,460



    -

     Decrease in other assets/liabilities 

    768



    -

     Net cash used in operating activities 

    (19,466)



    (87,391)









     Cash flows from investing activities   







     Capital expenditure 

    (2,444)



    (460)

     Interest received 

    7



    6

     Development costs capitalized 

    (16,254)



    (18,138)

     Acquisition of subsidiary, net of cash acquired 

    (13,835)



    -

     Proceeds from sale of investment in subsidiary 

    2,213



    -

     Purchase of shares in associates and joint ventures 

    (5,000)



    (5,000)

     Net cash used in investing activities 

    (35,313)



    (23,592)









     Cash flows from financing activities 







     Proceeds from other loans 

    116



    357

     Payments from exercise of share options 

    (482)



    -

     Net proceeds from issue of share capital 

    -



    1

     Fees directly attributable to equity raise 

    -



    (10,245)

     Principle payments on leases 

    (2,293)



    (782)

     Interest paid 

    (1,826)



    (2,338)

     Net cash outflow from financing activities 

    (4,485)



    (13,007)

     Net (decrease) in cash and cash equivalents 

    (59,264)



    (123,990)

     Cash and cash equivalents at January 1 

    101,757



    214,888

     Effect of movements in exchange rate on cash held 

    (112)



    (702)

     Cash and cash equivalents at June 30 

    $ 42,381



    $ 90,196

     

     

    Table 3

    Babylon Holdings Limited

    Consolidated Statement of Financial Position

    (In thousands, unaudited)





     June 30,



     December 31, 



    2021



    2020

     ASSETS 







     Non-current assets 







     Right-of-use assets 

    $ 10,135



    $ 2572

     Property, plant and equipment 

    2,879



    1,334

     Investments in associates 

    12,600



    8,876

     Goodwill 

    31,303



    17,832

     Other intangible assets 

    102,331



    78,853

     Total non-current assets 

    159,248



    109,467

     Current assets 







     Right-of-use assets 

    3,487



    1,942

     Trade and other receivables 

    28,218



    13,525

     Prepayments and contract assets 

    9,253



    8,841

     Cash and cash equivalents 

    42,381



    101,757

     Assets held for sale 

    -



    3,282

     Total current assets 

    83,339



    129,347

     Total assets 

    $ 242,587



    $ 238,814









     EQUITY AND LIABILITIES 







     Ordinary share capital 

    $ 10



    $ 10

     Preference share capital 

    4



    3

     Share premium 

    557,569



    485,221

     Share-based payment reserve 

    45,286



    32,185

     Retained earnings 

    (544,411)



    (469,504)

     Foreign currency translation reserve 

    1,608



    1,675

     Total capital and reserves  

    60,066



    49,590

        Non-controlling interests 

    (2,046)



    (1,231)

     Total equity 

    58,020



    48,359









     LIABILITIES 







     Non-current liabilities 







     Contract liabilities 

    81,982



    57,274

     Deferred grant income – tax credit 

    6,340



    7,488

     Lease liabilities 

    10,815



    2,011

     Deferred tax liability 

    768



    -

     Total non-current liabilities 

    99,905



    66,773

     Current liabilities 







     Trade and other payables 

    26,231



    11,635

     Accruals and provisions 

    31,574



    18,636

     Contract liabilities 

    23,136



    18,744

     Deferred grant income – tax credit 

    1,264



    -

     Lease liabilities 

    1,984



    2,488

     Loans and borrowings 

    473



    70,357

     Liabilities directly associated with the assets held for sale 

    -



    1,822

     Total current liabilities 

    84,662



    123,682

     Total liabilities 

    184,567



    190,455

     Total liabilities and equity 

    $ 242,587



    $ 238,814



     

     

    EBITDA is defined as profit (loss), adjusted for depreciation, amortization, net finance income (costs), and income taxes. Adjusted EBITDA is defined as profit (loss), adjusted for depreciation, amortization, net finance income (costs), income taxes, share-based compensation, impairment expenses, foreign exchange gains or losses and gains or losses on sale of subsidiaries.

    We believe that EBITDA and Adjusted EBITDA are useful metrics for investors to understand and evaluate our operating results and ongoing profitability because it permits investors to evaluate our recurring profitability from our ongoing operating activities.

    EBITDA and Adjusted EBITDA have certain limitations, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under IFRS. We caution investors that amounts presented in accordance with our definition of EBITDA and Adjusted EBITDA may not be comparable to similar measures disclosed by other issuers, because some issuers calculate EBITDA and Adjusted EBITDA differently or not at all, limiting their usefulness as direct comparative measures. 

     

     

    Table 4

    Babylon Holdings Limited

    Reconciliation of IFRS Loss for the Period to EBITDA and Adjusted EBITDA

    (In thousands, unaudited)







    Six Months Ended June 30,





    2021



    2020

    Loss for the period



    (75,722)



    (90,813)

    Add:









    Depreciation and amortization expenses



    13,322



    6,459

    Finance costs and income



    2,215



    2,563

    Tax (benefit) / provision on loss



    (2,493)



    2,937

    EBITDA



    (62,678)



    (78,854)

    Share-based compensation



    12,344



    433

    Impairment expense



    -



    32

    Exchange loss



    91



    2,146

    Gain on sale of subsidiary



    (3,917)



    -

    Adjusted EBITDA



    (54,160)



    (76,243)

     

    Additional Information and Where to Find It

    In connection with the proposed business combination between Alkuri Global Acquisition Corp. ("Alkuri Global") and Babylon Holdings Limited ("Babylon") and the other parties to the Merger Agreement dated June 3, 2021 (the "Merger Agreement"), Babylon filed a registration statement on Form F-4 dated July 2, 2021 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") with respect to Babylon's securities to be issued in connection with the proposed business combination (File No. 333-257694), and Alkuri Global intends to file a preliminary proxy statement in connection with Alkuri Global's solicitation of proxies for the vote by Alkuri Global's stockholders in connection with the proposed business combination and other matters as described in the proxy statement, as well as the preliminary prospectus relating to the offer of the securities to be issued to Alkuri Global's stockholders in connection with the completion of the business combination. After the Registration Statement is declared effective, Alkuri Global shall mail a definitive proxy statement and other relevant documents to its stockholders as of the record date established for voting on the proposed business combination. Alkuri Global's stockholders and other interested persons are advised to read the Registration Statement and any amendments thereto and, once available, the definitive proxy statement/consent solicitation/prospectus, in connection with Alkuri Global's solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the proposed business combination (the "Special Meeting"), because these documents will contain important information about Alkuri Global, Babylon and the proposed business combination.

    Alkuri Global's stockholders may also obtain a copy of the preliminary proxy statement/prospectus, or definitive proxy statement/prospectus once available, as well as other documents filed with the SEC regarding the proposed business combination and other documents filed with the SEC by Alkuri Global, without charge, at the SEC's website located at www.sec.gov or by directing a request to: Alkuri Global Acquisition Corp., 4235 Hillsboro Pike, Suite 300, Nashville, TN 37215, Attention: Secretary, (615) 632-0303.

    Participants in Solicitation

    Alkuri Global, Babylon, and their respective directors and officers may be deemed participants in the solicitation of proxies of Alkuri Global stockholders in connection with the proposed business combination. Alkuri Global stockholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Alkuri Global in Alkuri Global's registration statement on Form S-1 (File No. 333-251832), which was declared effective by the SEC on February 4, 2021. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Alkuri Global stockholders in connection with the proposed business combination and other matters to be voted upon at its Special Meeting will be set forth in the proxy statement/prospectus for the proposed business combination when available. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed business combination will be included in the Registration Statement that Babylon intends to file with the SEC.

    Forward-Looking Statements

    This communication contains, and certain oral statements made by representatives of Babylon and Alkuri Global and their respective affiliates, from time to time may contain, a number of "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, without limitation, information concerning Babylon's or Alkuri Global's possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment, potential growth opportunities, Babylon's and Alkuri Global's expectations with respect to the future performance of the combined company, including whether this proposed business combination will generate returns for stockholder, the anticipated addressable market for the combined company, the satisfaction of the closing conditions to the business combination, and the timing of the transaction.

    These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Babylon's or Alkuri Global's management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement and the proposed business combination contemplated thereby; (b) the inability to complete the proposed business combination due to the failure to obtain approval of the stockholders of Alkuri Global or other conditions to closing in the Merger Agreement; (c) the ability to meet Nasdaq's listing standards following the consummation of the proposed business combination; (d) the failure of investors in the PIPE to fund their commitments upon the closing of the proposed business combination; (e) the risk that the proposed business combination disrupts current plans and operations of Babylon or its subsidiaries as a result of the announcement and consummation of the transactions described herein; (f) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (g) costs related to the proposed business combination; (h) changes in applicable laws or regulations, including legal or regulatory developments (such as the SEC's recently released statement on accounting and reporting considerations for warrants in SPACs) which could result in the need for Alkuri Global to restate its historical financial statements and cause unforeseen delays in the timing of the business combination and negatively impact the trading price of Alkuri Global's securities and the attractiveness of the business combination to investors; (i) the possibility that Babylon may be adversely affected by other economic, business and/or competitive factors; and (j) other risks and uncertainties to be identified in the registration/proxy statement relating to the business combination, when available, and in other documents filed or to be filed with the SEC by Alkuri Global and Babylon and available at the SEC's website at www.sec.gov.

    Babylon and Alkuri Global caution that the foregoing list of factors is not exclusive, and caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, neither Alkuri Global nor Babylon undertakes any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this release.

    No Offer or Solicitations

    This communication is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities pursuant to the proposed business combination or otherwise, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    No Assurances

    There can be no assurance that the proposed business combination will be completed, nor can there be any assurance, if the proposed business combination is completed, that the potential benefits of combining the companies will be realized.

    Contacts:

    Media

    Adam Davison

    [email protected]

    Investors

    Kathy Kress

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/babylon-delivers-exceptional-h1-2021-operational-and-financial-results-and-reaffirms-growth-guidance-301377556.html

    SOURCE Babylon

    Get the next $KURI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KURI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KURI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Babylon, one of the world's fastest-growing digital healthcare companies, to begin trading on the New York Stock Exchange under the ticker BBLN

      PALO ALTO, Calif. and LONDON, Oct. 21, 2021 /PRNewswire/ -- Babylon Holdings Limited ("Babylon"), one of the world's fastest-growing digital healthcare companies, today announced that it has completed its business combination with Alkuri Global Acquisition Corp. (NASDAQ:KURI, KURIU and KURIW))) ("Alkuri"), a special purpose acquisition company. The transaction was approved on October 20, 2021 by Alkuri's shareholders. Babylon's Class A ordinary shares and its warrants will begin trading on the New York Stock Exchange ("NYSE") on October 22, 2021 under the new ticker symbols "BBLN" and "BBLN.W", respectively. "We founded Babylon on a fundamental belief, that it is possible to make quality hea

      10/21/21 4:03:00 PM ET
      $KURI
    • Babylon accelerates momentum, more than doubling its signed value-based care lives in the second half of this year so far

      PALO ALTO, Calif., Oct. 18, 2021 /PRNewswire/ -- Babylon today outlined its ongoing momentum, announcing a further c.135k lives will have access to its value-based care offering across the US and UK through its expansion to additional US states, Georgia and Mississippi, and further growth across California. This means that through a combination of its value-based care model, Babylon 360 and its work in primary care, Babylon will be managing c. 350k lives globally, including 105k NHS GP at Hand lives, by the start of 2022. Babylon reiterated 2021 and 2022 revenue guidance on September 15, 2021. "This expansion of our work will help Babylon further our aim of reaching communities where access

      10/18/21 3:27:00 AM ET
      $KURI
    • Babylon Secures New $200m Sustainability-Linked Investment to Fuel Rapid Growth Plan

      PALO ALTO, Calif. and LONDON, Oct. 8, 2021 /PRNewswire/ -- Babylon Holdings Limited ("Babylon"), one of the world's fastest-growing digital healthcare companies, today announced that it has secured a sustainability-linked investment of up to $200 million from Albacore Capital Group ("AlbaCore"), a strategic capital investment firm. Together with already committed PIPE capital of $230 million from institutional and strategic investors, Babylon will now have access to as much as $775 million of capital (before fees) following the merger with Alkuri Global Acquisition Corp. (NASDAQ:KURI, KURIU and KURIW))) ("Alkuri"), a publicly traded special purpose acquisition company, assuming no redemption

      10/8/21 1:30:00 AM ET
      $KURI

    $KURI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Williams Rich bought $32,004 worth of shares (3,175 units at $10.08)

      4 - ALKURI GLOBAL ACQUISITION CORP. (0001836967) (Issuer)

      10/19/21 9:12:21 PM ET
      $KURI

    $KURI
    Leadership Updates

    Live Leadership Updates

    See more
    • Babylon Appoints Stock Exchange Veteran as New Board Member Ahead of Public Listing

      PALO ALTO, Calif. and LONDON, Sept. 28, 2021 /PRNewswire/ -- Babylon today announced the appointment of US exchange veteran David Warren, who will join Babylon's board and serve as Chair of the Audit Committee when the company becomes publicly listed later this year. David will bring over two decades of US and UK public company experience to the Babylon board, as the company takes its final steps before listing on the New York Stock Exchange. As well as serving as CFO during his eight years at LSEG, he also held the position of interim Chief Executive Officer of the LSEG from 2018 to 2019. David had previously spent over 10 years working at Nasdaq, firstly as Chief Financial Officer from 20

      9/28/21 10:09:00 AM ET
      $KURI
    • Payoneer Announces the Appointment of Two Additional Board Members

      Payoneer Global Inc. ("Payoneer") (NASDAQ:PAYO), the commerce technology company powering payments and growth for the new global economy, today announced that Heather Tookes and Rich Williams were appointed to its Board of Directors. Prof. Tookes will also serve as a member of the Audit and Compensation Committees and Mr. Williams will serve as a member of the Audit and Risk Committees. "We are honored to welcome Heather and Rich as independent directors to our Board," said Scott Galit, Chief Executive Officer of Payoneer. "Heather brings considerable expertise in corporate finance and capital markets based on her extensive research and teaching at the Yale School of Management and brings

      7/20/21 8:00:00 AM ET
      $PAYO
      $KURI
      Business Services
      Consumer Discretionary

    $KURI
    SEC Filings

    See more
    • SEC Form 15-12B filed by Alkuri Global Acquisition Corp. common stock

      15-12B - ALKURI GLOBAL ACQUISITION CORP. (0001836967) (Filer)

      11/1/21 5:14:42 PM ET
      $KURI
    • SEC Form 25 filed by Alkuri Global Acquisition Corp. common stock

      25 - ALKURI GLOBAL ACQUISITION CORP. (0001836967) (Filer)

      10/22/21 6:00:27 AM ET
      $KURI
    • Alkuri Global Acquisition Corp. common stock filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits

      8-K - ALKURI GLOBAL ACQUISITION CORP. (0001836967) (Filer)

      10/22/21 6:01:30 AM ET
      $KURI